- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02487940
Assessment of Intralipid Efficacy in Women With Unexplained Recurrent Implantation Failure
Assessment of the Efficacy of Intralipid 20% in Management of Women With Unexplained Recurrent Implantation Failure in IVF Cycles: A Double Blinded Randomised Controlled Trial
The study will include 100 women with unexplained recurrent implantation failure undergoing IVF/ICSI cycle.
Patients fulfilling the inclusion criteria will be randomised into two groups.
Study Group:
This group will include 50 women with unexplained recurrent implantation failure undergoing a trial of IVF/ICSI. This group will receive intravenous infusion of intralipid 20%, on the day of oocyte retrieval, a second dose on/ the following day of positive pregnancy test and a final dose 2-3 weeks later when attending for pregnancy scan.
Control Group:
This group will include 50 women with unexplained recurrent implantation failure undergoing a trial of IVF/ICSI. This group will receive intravenous infusion of placebo, on the day of oocyte retrieval, a second dose on/ the following day of positive pregnancy test and a final dose 2-3 weeks later when attending for pregnancy scan.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will include 100 women with unexplained recurrent implantation failure undergoing IVF/ICSI cycle.
Randomisation:
Patients fulfilling the inclusion criteria will randomised to two groups.
Study Group:
This group will include 50 women with unexplained recurrent implantation failure undergoing a trial of IVF/ICSI. This group will receive intravenous infusion of intralipid 20%, on the day of oocyte retrieval, a second dose on/ the following day of positive pregnancy test and a final dose 2-3 weeks later when attending for pregnancy scan.
Control Group:
This group will include 50 women with unexplained recurrent implantation failure undergoing a trial of IVF/ICSI. This group will receive intravenous infusion of placebo, on the day of oocyte retrieval, a second dose on/ the following day of positive pregnancy test and a final dose 2-3 weeks later when attending for pregnancy scan.
Random allocation sequence generation:
A computer generated list will be used, assigning each participant number to either study groups.
Allocation Concealment:
Assignment will be done by sequentially numbered, otherwise identical, sealed envelopes (SNOSE), each containing a 2-inch by 2-inch paper with a written code designating the assigned group. These papers will be placed in a folded sheet of aluminium foil fitted inside the envelope. Effort will be taken to assure absence of any detectable differences in size or weight between intervention and control envelopes. Envelopes will be chosen to be opaque and lined inside with carbon paper. Envelopes will be opened sequentially only after writing the subject's tracking information on the envelope so that the carbon paper served as an audit trail.
Blinding:
Both drug with active ingredient and placebo will be provided by the hospital pharmacy in identical sealed opaque containers, equal in weight, similar in appearance, and tamper-proof. The drug with the active ingredient containers will be labeled either Group A or Group B by the head pharmacist and the assignment kept secret to be revealed after the end of the study.
Drugs will be administered to patients by a sealed opaque infusion drip.
IVF/ICSI cycle will be done using the standard LLP in both groups.
Primary outcome will be Live birth rates.
Secondary outcomes will be clinical pregnancy rates and side effects/tolerability of Intralipid infusion.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 20-38 years of age.
- Repeated implantation failure with 3 or more failed IVF cycles with good quality embryos.
- Normal trans-vaginal ultrasonography.
- Normal hysteroscopy.
- Normal male and female karyotyping.
- Normal anti cardiolipin antibody IGG, IGM and Lupus anticoagulant.
- Normal thrombophilia screen in the form of protein c, s, anti thrombin iii and factor v leiden.
- Written and signed informed consent by the patient to participate in the study.
Exclusion Criteria:
- Age more than 38 years.
- Less than 3 failed IVF cycles.
- Poor embryo quality.
- Expected poor ovarian response.
- Abnormal trans-vaginal ultrasound findings e.g. endometrial polyps or fibroids.
- Abnormal male or female karyotyping.
- Abnormal hysteroscopic finding e.g. endometrial polyps, endometrial hyperplasia, fibroid or congenital anomalies.
- Positive Anticardiolipin antibodies or Lupus anticoagulant.
- Positive thrombophilia screen.
- Allergy to soy oil, eggs, peanut, peanut-based products or any active ingredient in the infusion.
- Mental condition rendering the patients unable to understand the nature, scope and possible consequences of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Intralipid
Women with RIF received intralipid 20% (at a dose of 9mg/mL of the total blood volume, corresponding to 2 mL intralipid diluted at 20% in 250 mL normal saline) given over 1-2 hours on the day of oocyte retrieval.
Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
|
Women with RIF received intralipid 20% (at a dose of 9mg/mL of the total blood volume, corresponding to 2 mL intralipid diluted at 20% in 250 mL normal saline) given over 1-2 hours on the day of oocyte retrieval.
Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
Other Names:
|
Placebo Comparator: Placebo
Women with RIF received intravenous infusion of 250 mL physiological saline solution over 1-2 hours on the day of oocyte retrieval.
Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
|
Women with RIF received intravenous infusion of 250 mL physiological saline solution over 1-2 hours on the day of oocyte retrieval.
Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Live birth rates
Time Frame: up to 40 weeks gestation
|
up to 40 weeks gestation
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinical pregnancy rates
Time Frame: 6 weeks gestation (2 weeks following embryo transfer)
|
6 weeks gestation (2 weeks following embryo transfer)
|
side effects and tolerability of Intralipid
Time Frame: up to 40 weeks gestation
|
up to 40 weeks gestation
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Mostafa Gomaa, MD, Ain Shams univeristy hospitals
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ASUH1234
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Subfertility
-
University of NottinghamRecruitingInfertility, SubfertilityUnited Kingdom
-
University Hospital Schleswig-HolsteinCompletedInfertility, SubfertilityNorway, Germany
-
Australian Concept Medical CenterCompletedSubfertility, Female
-
University of Roma La SapienzaCompletedFemale Infertility | Female Subfertility
-
Turgut AydınRecruitingSubfertility, Female | Ovulation DisorderTurkey
-
Navy General Hospital, BeijingUnknownSubfertility, Female | Ovulation DisorderChina
-
Azienda Ospedaliera Città della Salute e della...UnknownOligospermia | Male Subfertility | Teratospermia | AsthenospermiaItaly
-
Infertility Treatment Center DortmundFerring Pharmaceuticals; TU Dortmund UniversityCompletedEnvironmental Exposure to Harmful Algae and Toxins | Female SubfertilityGermany
-
Radboud University Medical CenterGoodlife Fertility B.V.Active, not recruitingMale SubfertilityNetherlands
-
Ain Shams UniversityUnknownSubfertility, FemaleEgypt
Clinical Trials on Intralipid 20%
-
Indiana UniversityActive, not recruitingComparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical NeonatesCholestasis of Parenteral NutritionUnited States
-
Fresenius KabiTerminatedHospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 DaysUnited States
-
Fresenius KabiTerminatedMalnutrition, ChildUnited States
-
Woman's Health University Hospital, EgyptCompleted
-
Ain Shams UniversityRecruiting
-
Cairo UniversityCompleted
-
Emory UniversityAmerican Heart AssociationCompletedHypertension | Endothelial DysfunctionUnited States
-
Ain Shams UniversityUnknown
-
Methodist Research Institute, IndianapolisTerminatedAcute Respiratory Distress SyndromeUnited States
-
Nkanyiso HadebeUnknown